Abstract
Aims: Evaluating the benefit of telemonitoring in heart failure (HF) management in real‐world settings is crucial for optimizing the healthcare pathway. The aim of this study was to assess the association between a 6‐month application of the telemonitoring solution Chronic Care Connect™ (CCC) and mortality, HF hospitalizations, and associated costs compared with standard of care (SOC) in patients with a diagnosis of HF.Methods and results: From February 2018 to March 2020, a retrospective cohort study was conducted using the largest healthcare insurance system claims database in France (Système National des Données de Santé) linked to the CCC telemonitoring database of adult patients with an ICD‐10‐coded diagnosis of HF. Patients from the telemonitoring group were matched with up to two patients from the SOC group based on their high‐dimensional propensity score, without replacement, using the nearest‐neighbour method. A total of 1358 telemonitored patients were matched to 2456 SOC patients. The cohorts consisted of high‐risk patients with median times from last HF hospitalization to index date of 17.0 (interquartile range: 7.0–66.0) days for the telemonitoring group and 27.0 (15.0–70.0) days for the SOC group. After 6 months, telemonitoring was associated with mortality risk reduction (hazard ratio [HR] 0.71, 95% confidence interval [CI] 0.56–0.89), a higher risk of first HF hospitalization (HR 1.81, 95% CI 1.55–2.13), and higher HF healthcare costs (relative cost 1.38, 95% CI 1.26–1.51). Compared with the SOC group, the telemonitoring group experienced a shorter average length of overnight HF hospitalization and fewer emergency visits preceding HF hospitalizations.Conclusion: The results of this nationwide cohort study highlight a valuable role for telemonitoring solutions such as CCC in the management of high‐risk HF patients. However, for telemonitoring solutions based on weight and symptoms, consideration should be given to implement additional methods of assessment to recognize imminent worsening of HF, such as impedance changes, as a way to reduce mortality risk and the need for HF hospitalizations. Further studies are warranted to refine selection of patients who could benefit from a telemonitoring system and to confirm long‐term benefits in high‐risk and stable HF patients.